Drugs in Dev. Gastroenterology
Phase I
Switzerland 
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Forbion
Deal Size : $100.0 million
Deal Type : Series B Financing
Granite Bio Debuts with $100 Million of Capital
Details : The financing aims to fund the development of Granite pipeline including GRT-001, it depletes pro-inflammatory monocytes, key drivers of autoimmunity and inflammation. It is being evaluated for IBD.
Product Name : GRT-001
Product Type : Antibody
Upfront Cash : Undisclosed
April 24, 2025
Lead Product(s) : GRT-001
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Forbion
Deal Size : $100.0 million
Deal Type : Series B Financing
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $425.0 million
Deal Type : Acquisition
Calypso Enters into Agreement to be Acquired by Novartis
Details : Novartis acquires CALY-002, a therapeutic antibody targeting Interleukin-15 for dermatology, gastrointestinal, and rheumatology applications.
Product Name : CALY-002
Product Type : Antibody
Upfront Cash : $250.0 million
August 01, 2024
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $425.0 million
Deal Type : Acquisition
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Kanyos Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KAN-101 is an investigational drug that aims to re-educate the immune cells that drive celiac disease, so they do not respond to gluten antigens, while leaving the healthy components of the immune system intact.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Kanyos Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Calypso Biotech has elected Celiac Disease and Eosinophilic Esophagitis to evaluate the biological and clinical efficacy of CALY-002. The study is a multi-site, randomized, placebo controlled single and multiple dose escalation study of an anti-IL-15 mAb...
Product Name : CALY-002
Product Type : Antibody
Upfront Cash : Inapplicable
November 16, 2020
Lead Product(s) : CALY-002
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims developing therapeutics for autoimmune diseases, to include Anokion’s lead antigen-specific drug candidate, KAN-101, for the treatment of celiac disease.
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 22, 2020
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Bristol Myers Squibb
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First-in-human study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten-free diet (GFD).
Product Name : KAN-101
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2020
Lead Product(s) : KAN-101
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
